Spark Therapeutics Stock
Your prediction
Pros and Cons of Spark Therapeutics in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Spark Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Spark Therapeutics | - | - | - | - | - | - | - |
| Ligand Pharmaceuticals | -1.540% | -3.759% | -7.246% | 118.803% | 54.217% | 316.260% | 167.056% |
| United Therapeutics | -2.040% | -2.019% | -3.756% | 84.880% | 6.740% | 104.989% | 194.258% |
| Ionis Pharmaceuticals Inc. | -2.030% | -5.964% | -34.579% | 21.707% | -32.019% | 27.978% | 47.510% |
News
London Stock Exchange Group H1 Earnings Call Highlights
Key Points
- Interested in London Stock Exchange Group plc? Here are five stocks we like better.
- LSEG delivered strong first-half results: Organic revenue grew 8.4%, adjusted EBITDA rose 14%
Palantir's Wild Ride: Inside the Stock Wall Street Can't Agree On
Key Points
- Interested in Palantir Technologies Inc.? Here are five stocks we like better.
- Palantir Technologies continues to post exceptional revenue growth, led by U.S. government and commercial
Dollar Tree’s Turnaround Is Starting to Take Root
Key Points
- Interested in Dollar Tree, Inc.? Here are five stocks we like better.
- Dollar Tree's board approved a $2.5 billion share repurchase in July 2026, arriving shortly after activist